Educational explainer
Compounded semaglutide in 2026
The FDA declared the semaglutide shortage resolved in February 2025[FDA], so identical-copy 503A compounding ended. Personalized formulations remain legal. This page explains what changed, what is still legal, and when a 503A preparation might make sense.
What ended in 2025
Under FDA shortage rules, 503A pharmacies were allowed to compound identical-copy semaglutide while supply was constrained. When the FDA confirmed supply had recovered, that allowance ended. Any 503A pharmacy still shipping a same-strength copy is now operating outside the compounding allowance.
What is still legal
503A pharmacies can still prepare personalized formulations under an individual prescription — a different dose, oral formulation, or an added ingredient like vitamin B12. This is a different legal lane than identical-copy and continues to be allowed for individual patient need.
Where the quality risk sits
Compounded preparations do not undergo FDA premarket approval, post-market pharmacovigilance reporting, or the same manufacturing oversight as brand product. Different 503A pharmacies have very different QA programs. A pharmacy doing HPLC potency testing + endotoxin + sterility validation is meaningfully different from one that does not. Treat the pharmacy as your unit of trust, not the category.
When a 503A preparation can make sense
- You have no insurance coverage for brand Wegovy or Zepbound and cash price is out of reach.
- You have a clinical reason for a personalized dose your prescriber documents.
- You and your prescriber have vetted the specific 503A pharmacy's QA program.
Brand-name providers (recommended first choice)
If you have insurance coverage or can afford brand product, that is the cleaner clinical path. Our brand-name provider rankings are here; they prescribe FDA-approved Wegovy, Zepbound, Saxenda, or Mounjaro — not compounded preparations.
Compounded-arm providers we have reviewed
Editorial coverage only — affiliate links live on each provider page but the primary call-to-action on this site is "read the review," not "sign up."
- Henry Meds
Compounded-first GLP-1 telehealth with three-tier pricing — the cash-only value pick.
From $179/mo⭐ 4.2compounded-503a
Read review - Noom
Behavioral-first program with GLP-1 access — coaching bundled in for adherence-heavy users.
From $149/mo⭐ 4.0compounded-503a
Read review - LifeMD
Full primary-care telehealth with GLP-1 — the pick for patients who want ongoing PCP integration.
From $249/mo⭐ 4.3hybrid
Read review - Push Health
Direct-to-doctor GLP-1 access — no subscription, pay per visit + medication.
From $75/mo⭐ 3.9compounded-503a
Read review - TrimRX
Cash-pay online GLP-1 program from $179/mo — compounded semaglutide + tirzepatide.
From $179/mo⭐ 3.7compounded-503a
Read review
Frequently asked
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality. Only brand-name semaglutide products (Wegovy, Ozempic, Rybelsus) hold FDA approval. Source: FDA Drug Compounding pages at fda.gov/drugs/human-drug-compounding (accessed 2026-06).
Is compounded semaglutide still legal in 2026?
Personalized 503A formulations (different dose, oral, added vitamin B12, etc., prescribed for an individual patient) remain legal. Identical-copy 503A compounding ended when the FDA declared the semaglutide shortage resolved. Source: FDA Drug Shortages Database, semaglutide shortage status update, fda.gov (accessed 2026-06).
What are the safety risks of compounded semaglutide?
Risks include incorrect dosing, contamination, and active-ingredient variation. Compounded products are not subject to the same pre-market review or post-market pharmacovigilance as FDA-approved drugs. For specific adverse-event reports, see the FDA MedWatch database (accessdata.fda.gov/scripts/medwatch) and Novo Nordisk public patient-safety statements at novonordisk.com — figures are updated by the manufacturer and FDA continuously; we do not republish point-in-time counts.
How much does compounded semaglutide cost compared to brand Wegovy?
Compounded telehealth programs typically advertise cash-pay tiers in the $149–$349/month range. Brand Wegovy list price and manufacturer savings programs (NovoCare savings card) are published at wegovy.com and novocare.com — confirm the current figures there before relying on them. Compounded is cheaper because it skips FDA pre-market review; that gap is the reason for the price difference.
How do I verify a 503A compounding pharmacy is legitimate?
Check that the pharmacy is licensed in your state (search your state board of pharmacy), registered with the FDA Drug Quality and Security Act database, and accredited by PCAB (Pharmacy Compounding Accreditation Board). Ask the pharmacy for their HPLC potency testing, endotoxin, and sterility validation records. A pharmacy that cannot provide testing documentation is a red flag.
Editorial position
We do not promote compounded preparations as a primary recommendation. Brand-name providers are the default. We cover the compounded arm because access matters — but we mark every page with this disclaimer so readers can make an informed call.